

China-based HaploX Biotechnology closes a \$32 million Series-A plus financing round

04 January 2018 | News

The company's technologies include tools for capturing circulating tumor DNA; extracting and amplifying ultra-low concentrations of DNA from liquid samples; performing tagged sequencing; and managing and analyzing the resulting data.



China-based company, HaploX that focuses on precision medicine and genetic data has closed a \$32 million Series A-plus financing round.

Participants in the round included SB China Venture Capital (SBCVC) and Kexin Capital, HaploX CEO and Founder Mingyan Xu said in an email. SBCVC previously led HaploX's 2016 Series A financing, which raised approximately \$10 million.

According to the company's website, its technologies include tools for capturing circulating tumor DNA; extracting and amplifying ultra-low concentrations of DNA from liquid samples; performing tagged sequencing; and managing and analyzing the resulting data.

HaploX also colunched the Chinese Cancer Sequencing Project in 2015 along with the Shenzhen Peoples' Hospital, according to the firm's website. The project aims to build China's first large-scale cancer gene database, and covers early screening, prognosis monitoring, and individualized medicine for more than 10,000 individuals from diagnosed and high-risk groups.